No Data
Express News | Hubei Biocause Pharmaceutical: CHINA BEST's premium income for 2024 is approximately 32.694 billion yuan.
A-shares in the Insurance sector decline, Hubei Biocause Pharmaceutical falls over 8%.
On December 11, GF Securities reported that Hubei Biocause Pharmaceutical fell by over 8%, with New China Life Insurance, The People's Insurance, China Life Insurance, and China Pacific Insurance also following the decline.
The A-shares financial stocks surged, with shanghai dzh limited hitting the ceiling.
On December 10, Gelonghui reported that shanghai dzh limited hit the upper limit, hubei biocause pharmaceutical, guosheng financial holding inc., and jiangxi tianli technology, inc. previously reached the upper limit, while sgsg science&technology, beijing compass technology development, shenzhen ysstech info-tech, dongxing, and east money information all increased by over 5%.
Express News | Hubei Biocause Pharmaceutical: Recently, the company's operational situation and the internal and external operating environment have not undergone significant changes.
Express News | Hubei biocause pharmaceutical: There are no significant matters regarding the company that should have been disclosed but were not.
Hubei Biocause Pharmaceutical (000627.SZ) appointed Long Fei as the general manager and chief financial officer.
Hubei Biocause Pharmaceutical (000627.SZ) announced that the board of directors will hold the tenth session on December 6, 2024...
No Data
